一例使用特立氟胺导致的迟发性肝损伤，应用更新后的RUCAM评估因果关系
A Case of Delayed Hepatic Injury Associated with Teriflunomide Use as Assessed for Causality Using the Updated RUCAM.
作者信息
Wurzburger Riana
机构信息
Department of Internal Medicine, University of New Mexico Hospital, UNM School of Medicine MSC08 47201, University of New Mexico, Albuquerque, NM 87131, USA.
出版信息
Case Reports Hepatol. 2022 Jun 15;2022:6331923. doi: 10.1155/2022/6331923. eCollection 2022.
Abstract
Teriflunomide is a pyrimidine synthesis inhibitor used in the treatment of multiple sclerosis that has in rare instances been associated with liver toxicity, though there are few documented cases. Here, we report a case of probable teriflunomide-induced liver injury as assessed for causality using the updated RUCAM. The liver injury occurred approximately nine months after teriflunomide initiation and improved with discontinuation of the drug and treatment with cholestyramine.
摘要
特立氟胺是一种用于治疗多发性硬化症的嘧啶合成抑制剂，在罕见情况下与肝毒性有关，不过记录在案的病例很少。在此，我们报告一例可能由特立氟胺引起的肝损伤病例，使用更新后的RUCAM评估因果关系。肝损伤发生在开始使用特立氟胺约九个月后，停药并用考来烯胺治疗后有所改善。
相似文献
1
A Case of Delayed Hepatic Injury Associated with Teriflunomide Use as Assessed for Causality Using the Updated RUCAM.一例使用特立氟胺导致的迟发性肝损伤，应用更新后的RUCAM评估因果关系
Case Reports Hepatol. 2022 Jun 15;2022:6331923. doi: 10.1155/2022/6331923. eCollection 2022.
2
Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.特异质性药物性肝损伤：对2014年至2019年初通过RUCAM评估因果关系并发表的46266例病例的分析
Front Pharmacol. 2019 Jul 23;10:730. doi: 10.3389/fphar.2019.00730. eCollection 2019.
3
Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?药物性肝损伤：为何在其问世 25 年后 Roussel Uclaf 因果关系评估方法（RUCAM）仍在使用？
Drug Saf. 2018 Aug;41(8):735-743. doi: 10.1007/s40264-018-0654-2.
4
Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases.亚洲草药性肝损伤及RUCAM在11160例已发表病例因果关系评估中的当前作用
J Clin Transl Hepatol. 2020 Jun 28;8(2):200-214. doi: 10.14218/JCTH.2020.00009. Epub 2020 Apr 24.
5
Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.使用罗塞尔·优克福因果关系评估方法（RUCAM）分析一项临床试验项目中的肝脏检查结果：直接凝血酶抑制剂希美加群的评估
Int J Clin Pharmacol Ther. 2008 Jul;46(7):327-39. doi: 10.5414/cpp46327.
6
Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature.雄激素性合成代谢类固醇致肝损伤：2 例病例报告，采用改良的 Roussel Uclaf 因果关系评估方法（RUCAM）评分和文献综合回顾进行因果关系评估。
BMJ Open Gastroenterol. 2020 Nov;7(1). doi: 10.1136/bmjgast-2020-000549.
7
Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.使用更新后的罗塞尔·优克福因果关系评估方法对新生儿和重症监护病房儿童药物性肝损伤进行因果关系评估。
Front Pharmacol. 2021 Dec 20;12:790108. doi: 10.3389/fphar.2021.790108. eCollection 2021.
8
A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale.替加环素用药后药物性肝损伤 1 例报告：更新的 RUCAM 诊断量表评估的组织病理学证据和可能的因果关系分级。
BMC Infect Dis. 2022 Apr 11;22(1):368. doi: 10.1186/s12879-022-07258-w.
9
Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.酪氨酸激酶抑制剂致转移性肾细胞癌患者严重肝损伤：两例病例使用更新的 RUCAM 评估因果关系并文献复习。
BMC Gastroenterol. 2022 Feb 5;22(1):49. doi: 10.1186/s12876-022-02121-3.
10
A Severe Case of Drug-Induced Liver Injury after Gemcitabine Administration: A Highly Probable Causality Grading as Assessed by the Updated RUCAM Diagnostic Scoring System.吉西他滨给药后发生的严重药物性肝损伤：根据更新的RUCAM诊断评分系统评估为高度可能的因果关系分级
Case Reports Hepatol. 2020 Oct 1;2020:8812983. doi: 10.1155/2020/8812983. eCollection 2020.
引用本文的文献
1
Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms.药物性自身免疫性肝炎：使用两种不同的经过验证的评分诊断算法进行可靠的因果关系评估。
Diagnostics (Basel). 2025 Jun 23;15(13):1588. doi: 10.3390/diagnostics15131588.
2
Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.基于鲁塞尔·优克福因果关系评估方法的特异质性药物性肝损伤中的人类白细胞抗原遗传学
Medicines (Basel). 2024 Apr 11;11(4):9. doi: 10.3390/medicines11040009.
3
Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.特应性药物性肝损伤问题的研究进展：由于使用 Roussel Uclaf 因果关系评估方法，新的临床和机制分析。
Int J Mol Sci. 2023 Jun 29;24(13):10855. doi: 10.3390/ijms241310855.
4
Treatment of Drug-Induced Liver Injury.药物性肝损伤的治疗
Biomedicines. 2022 Dec 21;11(1):15. doi: 10.3390/biomedicines11010015.
本文引用的文献
1
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.来氟米特诱导的肝损伤：印度和美国注册研究中的特征和结局差异。
Liver Int. 2022 Jun;42(6):1323-1329. doi: 10.1111/liv.15189. Epub 2022 Feb 15.
2
Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.与使用特立氟胺治疗多发性硬化症相关的肝毒性：病例报告。
Medicine (Baltimore). 2021 Dec 23;100(51):e28246. doi: 10.1097/MD.0000000000028246.
3
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.特立氟胺的长期安全性和有效性：随机TEMSO研究的九年随访
Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10.
4
RUCAM in Drug and Herb Induced Liver Injury: The Update.药物及草药所致肝损伤的RUCAM：最新进展
Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014.
5
Iron overload is rare in patients homozygous for the H63D mutation.铁过载在 H63D 突变纯合子患者中较为罕见。
Can J Gastroenterol Hepatol. 2014 Apr;28(4):198-202. doi: 10.1155/2014/468521.
6
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.随机试验口服特立氟胺治疗复发型多发性硬化症。
N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
Zotero 插件